Obesity
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
Studies of the neuromedin U-2 receptor gene in human obesity: evidence for the existence of two ancestral forms of the receptor.
|
15525579 |
2004 |
Obesity
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
A total of 289 Czech children and adolescents with early-onset obesity and 84 Danish obese adults were analyzed for variants in NMU.
|
16984985 |
2006 |
Albuminuria
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic Association of Albuminuria with Cardiometabolic Disease and Blood Pressure.
|
30220432 |
2018 |
Pediatric Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Compared with NMU-25, NMS had a significantly reduced maximum response in saphenous vein, and the Arg165Trp variant of NMU-25, associated with childhood-onset obesity, was without effect.
|
18987052 |
2009 |
Pediatric Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
From a large European multi-center study on childhood obesity, 4,528 children (2.0-9.9 years, mean age 6.0±1.8 SD; boys 52.2%) were randomly selected, stratifying by age, sex and country, and genotyped for tag single nucleotide polymorphisms (SNPs; rs6827359, T:C; rs12500837, T:C; rs9999653,C:T) of NMU gene, then haplotypes were inferred.
|
28235053 |
2017 |
Pediatric Obesity
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The rare NMU Arg165Trp variant cosegregated with childhood obesity in a Czech family.
|
16984985 |
2006 |
Overweight and obesity
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Amino acid variants in NMU associate with overweight and obesity, suggesting that NMU is involved in energy regulation in humans.
|
16984985 |
2006 |
Obesity
|
0.250 |
Biomarker
|
disease |
BEFREE |
Recently, there has been an increased focus on NMU as a promising treatment option for diabetes and obesity.
|
28657315 |
2017 |
Obesity
|
0.250 |
Biomarker
|
disease |
RGD |
After 1 month of the high-fat diet, however, the obesity-resistant rats showed significantly more NMU-induced physical activity compared to the obese DIO rats.
|
17706946 |
2007 |
Obesity
|
0.250 |
Biomarker
|
disease |
BEFREE |
Screening of neuromedin U2 receptor (NMU2R) ligands may be very useful to treat obesity for the reason that centrally administered neuromedin U affects feeding behavior, energy expenditure, and pituitary.
|
16111886 |
2005 |
Obesity
|
0.250 |
Biomarker
|
disease |
BEFREE |
These results suggest that PEGylated NMU-8 has the therapeutic potential for treatment of obesity.
|
28400225 |
2017 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Thus, these results not only reveal the presence of previously uncharacterized heteromeric relationships among NMU receptors but also provide NMUR2S as a potential therapeutic target for the future treatment of NMU signaling-mediated cancers.
|
26317338 |
2015 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Although NmU exerted no effects on cancer cell proliferation, it induced c-Met and a trend towards increased invasiveness as well as an increased hepatocyte growth factor (HGF)-mediated scattering.
|
19118941 |
2009 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Neuromedin U: A Small Peptide in the Big World of Cancer.
|
31492042 |
2019 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In conclusion, NMU is a RhoGDI2-regulated gene that appears important for tumorigenicity, lung metastasis and cancer cachexia, and thus a promising therapeutic target in cancer.
|
16878152 |
2007 |
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U.
|
29107108 |
2018 |
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia.
|
16878152 |
2007 |
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
In vivo studies revealed that NmU attenuation impaired tumor growth and metastasis.
|
24876102 |
2014 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In vivo studies revealed that NmU attenuation impaired tumor growth and metastasis.
|
24876102 |
2014 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Furthermore, NMU-overexpressing xenografts were associated with lower animal body weight than control tumors, indicating a possible role of NMU in cancer cachexia.
|
16878152 |
2007 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Our results demonstrated that CPF increases tumor incidence and reduces latency of NMU-induced mammary tumors.
|
30290214 |
2019 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Neuromedin U (NMU) has been shown driving the progression of various tumor entities, including breast cancer.
|
28423716 |
2017 |
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
An analysis of 3,489 cases of breast cancer showed NmU to be associated with poor patient outcome, particularly those with HER2-overexpressing tumors independent of established prognostic indicators.
|
24876102 |
2014 |
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Next, the biological impact of NMU on breast cancer cells in relation to NMUR2 expression was analyzed.
|
28423716 |
2017 |
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Taken together, our results report a new mechanism-of-action for NmU in HER2-overexpressing breast cancer that enhances resistance to the anti-tumor immune response.
|
29209569 |
2017 |